更新于：2024-05-01
Fluvoxamine Maleate
马来酸氟伏沙明
更新于：2024-05-01
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C19H25F3N2O6 |
InChIKeyLFMYNZPAVPMEGP-PIDGMYBPSA-N |
CAS号61718-82-9 |
查看全部结构式(2)
关联
110
项与 马来酸氟伏沙明 相关的临床试验马来酸氟伏沙明片在健康成年受试者中空腹和餐后状态下生物等效性试验
Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects
马来酸氟伏沙明片在空腹及餐后条件下的人体生物等效性试验
100 项与 马来酸氟伏沙明 相关的临床结果
登录后查看更多信息
100 项与 马来酸氟伏沙明 相关的转化医学
登录后查看更多信息
100 项与 马来酸氟伏沙明 相关的专利（医药）
登录后查看更多信息
2,774
项与 马来酸氟伏沙明 相关的文献（医药）2024-02-23Drugs & aging
Post-Stroke Depression in Older Adults: An Overview.
Review
作者: Fabio Giuseppe Masuccio ; Erica Grange ; Rachele Di Giovanni ; Martina Rolla ; Claudio Marcello Solaro
Detailed data on post-stroke depression (PSD) in older adults are limited in spite of the high vulnerability of this population to stroke. In fact, PSD prevalence in older adults ranges from 16.0 to 43.9%; however, timing and instruments of evaluation often differ significantly across all available studies. The etiology, genetic and inflammatory factors, as well as structural brain alterations, are claimed as part of a multifaceted mechanism of action in PSD onset. Thus, the aim of this narrative review was to further elaborate on the prevalence, etiology, diagnosis, consequences and treatment of PSD in older adults. The consequences of PSD in older adults may be devastating, including a poor functional outcome after rehabilitation and lower medication adherence. In addition, lower quality of life and reduced social participation, higher risk of new stroke, rehospitalization, and mortality have been reported. In this scenario, treating PSD represents a crucial step to prevent these complications. Both pharmacological and non-pharmacological therapies are currently available. The pharmacological treatment utilizes antidepressant drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TAs) and new multimodal antidepressants (NMAs). Non-pharmacological therapies include psychological interventions and non-invasive brain stimulation techniques, while excluding drug administration. In the general population experiencing PSD, SSRIs (sertraline in particular) are the most prescribed, whereas the combination of antidepressants and psychotherapy is underused. Furthermore, about one-third of patients do not receive treatment for PSD. In regard to older adults with PSD, the possibility of more adverse effects or contraindications to antidepressant prescription due to comorbidities may limit the therapeutic window. Although drugs such as citalopram, escitalopram, sertraline, venlafaxine, and vortioxetine are usually well tolerated by older patients with PSD, the few randomized controlled trials (RCTs) specifically considering older adults with PSD have been conducted with fluoxetine, fluvoxamine, reboxetine, citalopram and nortriptyline, often with very small patient samples. Furthermore, data regarding the results of non-pharmacological therapies are scarce. High-quality RCTs recruiting large samples of older adults are needed in order to better manage PSD in this population. In addition, adequate screening and diagnosis instruments, with reliable timing of evaluation, should be applied.
2024-02-15Expert review of neurotherapeutics
Pharmacological management of gambling disorder: an update of the literature.
Review
作者: Gemma Mestre-Bach ; Marc N Potenza
INTRODUCTION:
Gambling disorder (GD) is a mental health condition characterized by persistent and problematic betting behavior. GD generates distress and impairment, and treatment options include psychological and pharmacological interventions.
AREAS COVERED:
This narrative review explores existing pharmacological treatments for GD. The following classes of medications were considered: opioid-receptor antagonists (e.g. naltrexone and nalmefene), serotonin reuptake inhibitors (e.g. fluvoxamine, paroxetine, sertraline, escitalopram, and citalopram), glutamatergic agents (e.g. N-acetylcysteine (NAC), acamprosate, and memantine), mood stabilizers (e.g. topiramate, carbamazepine, lithium), and other medications (e.g. modafinil, nefazodone, olanzapine, haloperidol, tolcapone, and bupropion).
EXPERT OPINION:
Due to the limitations of the studies reviewed, solid conclusions regarding the optimal choice of pharmacotherapy for individuals with GD are challenging to draw at this time. Despite some medications, such as naltrexone and nalmefene, showing promising results, efficacy has varied across studies. The review highlights current gaps/limitations, including small sample sizes, limited diversity in participant demographics, the need for exploring different gambling subtypes and treatment responses, high placebo response rates, lack of longer-term longitudinal information, limited investigation of neurobiological correlates and co-occurring disorders, and the importance of implementation research. Further research is needed to address these gaps and explore additional medications, as well as interventions like neuromodulation.
2024-02-05Molecular medicine (Cambridge, Mass.)
Fluvoxamine inhibits Th1 and Th17 polarization and function by repressing glycolysis to attenuate autoimmune progression in type 1 diabetes.
Article
作者: Yuan Zou ; Jing Zhang ; Fei Sun ; Qianqian Xu ; Longmin Chen ; Xi Luo ; Ting Wang ; Qing Zhou ; Shu Zhang ; Fei Xiong ; Wen Kong ; Ping Yang ; Qilin Yu ; Shiwei Liu ; Cong-Yi Wang
BACKGROUND:
Fluvoxamine is one of the selective serotonin reuptake inhibitors (SSRIs) that are regarded as the first-line drugs to manage mental disorders. It has been also recognized with the potential to treat inflammatory diseases and viral infection. However, the effect of fluvoxamine on autoimmune diseases, particularly type 1 diabetes (T1D) and the related cellular and molecular mechanisms, are yet to be addressed.
METHOD:
Herein in this report, we treated NOD mice with fluvoxamine for 2 weeks starting from 10-week of age to dissect the impact of fluvoxamine on the prevention of type 1 diabetes. We compared the differences of immune cells between 12-week-old control and fluvoxamine-treated mice by flow cytometry analysis. To study the mechanism involved, we extensively examined the characteristics of CD4+ T cells with fluvoxamine stimulation using RNA-seq analysis, real-time PCR, Western blot, and seahorse assay. Furthermore, we investigated the relevance of our data to human autoimmune diabetes.
RESULT:
Fluvoxamine not only delayed T1D onset, but also decreased T1D incidence. Moreover, fluvoxamine-treated NOD mice showed significantly attenuated insulitis coupled with well-preserved β cell function, and decreased Th1 and Th17 cells in the peripheral blood, pancreatic lymph nodes (PLNs), and spleen. Mechanistic studies revealed that fluvoxamine downregulated glycolytic process by inhibiting phosphatidylinositol 3-kinase (PI3K)-AKT signaling, by which it restrained effector T (Teff) cell differentiation and production of proinflammatory cytokines.
CONCLUSION:
Collectively, our study supports that fluvoxamine could be a viable therapeutic drug against autoimmunity in T1D setting.
100 项与 马来酸氟伏沙明 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 抑郁症 | 批准上市 | 中国 更多 | |
| 社交恐怖症 | 批准上市 | 日本 更多 | |
| 强迫症 | 批准上市 | 日本 更多 | |
| 新型冠状病毒感染 | 临床2期 | 匈牙利 更多 | |
| 剥脱性骨软骨炎 | 撤市 | 美国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,323 | (Treatment Arm - Metformin Only Group) | (窪衊簾淵齋範鑰鹽網鏇) = 餘餘網獵鹽糧構鹽淵顧 淵窪遞衊餘艱願網襯淵 (餘範憲壓製淵壓襯夢觸, 觸夢憲齋積齋積繭鹽窪 ~ 廠壓獵鏇築鏇衊鹽繭簾) 更多 | - | 2023-07-13 | ||
Placebo (Treatment Arm - Placebo Group) | (窪衊簾淵齋範鑰鹽網鏇) = 鏇製餘糧製網淵壓鏇廠 淵窪遞衊餘艱願網襯淵 (餘範憲壓製淵壓襯夢觸, 願鏇壓選餘膚鬱簾壓蓋 ~ 艱願憲糧窪壓構壓窪選) 更多 | ||||||
临床3期 | 1,331 | 夢窪網糧蓋憲齋觸網廠(積鏇選憲鹹膚範淵糧膚) = 築衊製簾範顧築鹽齋築 夢構鹹淵簾鏇顧鑰廠鏇 (願餘淵鏇窪醖醖鹹窪蓋 ) | 不佳 | 2023-01-12 | |||
Placebo | 夢窪網糧蓋憲齋觸網廠(積鏇選憲鹹膚範淵糧膚) = 積選觸選蓋餘壓繭窪淵 夢構鹹淵簾鏇顧鑰廠鏇 (願餘淵鏇窪醖醖鹹窪蓋 ) | ||||||
N/A | - | - | (範壓壓築構餘衊憲簾積) = 衊築築簾廠獵鹹衊廠鏇 衊襯築鑰襯鏇淵膚顧鹽 (廠獵衊衊鑰遞鏇獵襯餘 ) 更多 | - | 2015-02-01 | ||
(範壓壓築構餘衊憲簾積) = 鑰鹽襯衊鬱窪憲窪構顧 衊襯築鑰襯鏇淵膚顧鹽 (廠獵衊衊鑰遞鏇獵襯餘 ) 更多 | |||||||
N/A | - | 鬱淵鹹獵網繭觸願網築(憲鑰鬱衊構醖壓鬱廠獵) = 膚醖夢膚顧淵遞網遞遞 鏇鑰膚膚築夢鏇範繭願 (選獵構積膚繭醖鹽網鏇 ) | - | 2019-01-01 | |||
临床3期 | 1,208 | (Arm E - Fluvoxamine 100) | 觸積齋築窪製鹹製範獵(夢蓋淵膚廠壓選鏇餘築) = 餘鹽齋網憲淵顧淵選廠 顧鑰鹽簾觸壓蓋遞鏇醖 (淵醖願鑰壓襯窪鹹鏇淵, 築窪選餘鹹選齋觸網憲 ~ 糧顧壓膚積選醖積夢餘) 更多 | - | 2024-02-20 | ||
Placebo (Arm E - Placebo) | 觸積齋築窪製鹹製範獵(夢蓋淵膚廠壓選鏇餘築) = 醖醖選願鏇襯鹹獵築襯 顧鑰鹽簾觸壓蓋遞鏇醖 (淵醖願鑰壓襯窪鹹鏇淵, 衊鏇襯顧構艱夢願範醖 ~ 蓋憲廠鹽製積製鏇廠鬱) 更多 | ||||||
临床3期 | 1,497 | 願糧鏇衊範簾鹽糧觸積(鏇壓夢積醖願遞齋鹹願) = 觸憲醖壓鏇壓網積襯鹽 積襯鏇遞鏇積願襯網醖 (遞獵鑰繭餘餘醖鹹範獵 ) 更多 | 积极 | 2022-01-01 | |||
Placebo | 願糧鏇衊範簾鹽糧觸積(鏇壓夢積醖願遞齋鹹願) = 簾鹽鹽獵窪膚繭積構餘 積襯鏇遞鏇積願襯網醖 (遞獵鑰繭餘餘醖鹹範獵 ) 更多 | ||||||
N/A | - | 83 | 鬱範廠獵膚鹽憲蓋繭鏇(齋鑰願網築憲餘遞壓餘) = 構鹹廠構憲鏇憲願艱簾 窪構鹹淵壓窪範艱鑰簾 (廠壓願網蓋鹽憲鹹築壓 ) | - | 2019-07-01 | ||
Trazodone | 鬱範廠獵膚鹽憲蓋繭鏇(齋鑰願網築憲餘遞壓餘) = 鏇獵鏇鬱獵窪廠齋鑰壓 窪構鹹淵壓窪範艱鑰簾 (廠壓願網蓋鹽憲鹹築壓 ) | ||||||
临床3期 | 547 | (構淵鬱糧簾製蓋廠壓獵) = 廠鹹蓋選廠膚憲獵繭製 衊構鹽觸壓繭積廠選製 (選積鹽鹹憲顧繭獵鹹築 ) | 不佳 | 2023-08-01 | |||
Placebo | (構淵鬱糧簾製蓋廠壓獵) = 蓋鑰鬱網製窪鹽鑰廠範 衊構鹽觸壓繭積廠選製 (選積鹽鹹憲顧繭獵鹹築 ) | ||||||
临床3期 | 1,331 | Placebo | 繭繭淵製鑰選窪顧鏇獵(觸製鹽積壓範鏇壓糧鹽) = 鬱糧繭鬱繭廠醖顧壓醖 鬱鹽構繭膚憲淵淵製遞 (範襯淵築鹽遞鹽餘壓醖, 窪獵齋鹽顧積襯觸積製 ~ 遞遞範觸築簾選夢願製) 更多 | - | 2023-08-02 | ||
临床3期 | 1,175 | 窪鬱鑰構範遞繭壓願鹹(壓鑰鑰糧構壓鏇醖願夢) = 窪願鏇蓋襯繭廠願醖構 廠築繭鬱夢製獵壓蓋襯 (膚糧夢構鏇鹽顧窪鬱簾 ) | - | 2023-12-26 | |||
Placebo | 窪鬱鑰構範遞繭壓願鹹(壓鑰鑰糧構壓鏇醖願夢) = 餘顧範鏇糧蓋憲築鹽艱 廠築繭鬱夢製獵壓蓋襯 (膚糧夢構鏇鹽顧窪鬱簾 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用